[{"address1": "409 Illinois Street", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 978 1200", "fax": "415 978 1902", "website": "https://www.fibrogen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.", "fullTimeEmployees": 486, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thane  Wettig", "age": 58, "title": "CEO & Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 807345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Juan  Graham", "age": 46, "title": "Senior VP & CFO", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 991757, "exercisedValue": 0, "unexercisedValue": 221113}, {"maxAge": 1, "name": "Ms. Christine L. Chung", "age": 55, "title": "Senior Vice President of China Operations", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 1274738, "exercisedValue": 0, "unexercisedValue": 104427}, {"maxAge": 1, "name": "Dr. Barry A. Berkowitz Ph.D.", "title": "Founder", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John J. Hunter Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "David  DeLucia", "title": "Vice President of Corporate FP&A and Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Lowenstein J.D., Ph.D.", "title": "Chief Legal Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tricia  Stewart", "title": "Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kirk A. Christoffersen MBA", "age": 54, "title": "Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rahul Rajan Kaushik Ph.D.", "title": "Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 2, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.63, "open": 1.62, "dayLow": 1.485, "dayHigh": 1.63, "regularMarketPreviousClose": 1.63, "regularMarketOpen": 1.62, "regularMarketDayLow": 1.485, "regularMarketDayHigh": 1.63, "beta": 0.664, "forwardPE": -3.511628, "volume": 1011650, "regularMarketVolume": 1011650, "averageVolume": 2871259, "averageVolume10days": 2527980, "averageDailyVolume10Day": 2527980, "bid": 1.5, "ask": 1.51, "bidSize": 200, "askSize": 200, "marketCap": 149144512, "fiftyTwoWeekLow": 0.333, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 1.0094247, "fiftyDayAverage": 2.0475, "twoHundredDayAverage": 1.41747, "currency": "USD", "enterpriseValue": 231665824, "profitMargins": -1.92371, "floatShares": 82986614, "sharesOutstanding": 98771200, "sharesShort": 5528307, "sharesShortPriorMonth": 7209198, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.055999998, "heldPercentInsiders": 0.06368, "heldPercentInstitutions": 0.71449, "shortRatio": 3.12, "shortPercentOfFloat": 0.0736, "impliedSharesOutstanding": 106501000, "bookValue": -2.067, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -284232000, "trailingEps": -2.92, "forwardEps": -0.43, "enterpriseToRevenue": 1.568, "enterpriseToEbitda": -0.816, "52WeekChange": -0.91933763, "SandP52WeekChange": 0.27320957, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FGEN", "underlyingSymbol": "FGEN", "shortName": "FibroGen, Inc", "longName": "FibroGen, Inc.", "firstTradeDateEpochUtc": 1415975400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "36a357a0-624b-3e04-a14d-dbb6b1255b8f", "messageBoardId": "finmb_28484", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.51, "targetHighPrice": 2.0, "targetLowPrice": 1.5, "targetMeanPrice": 1.75, "targetMedianPrice": 1.75, "recommendationMean": 3.7, "recommendationKey": "underperform", "numberOfAnalystOpinions": 2, "totalCash": 235586000, "totalCashPerShare": 2.385, "ebitda": -283915008, "totalDebt": 170455008, "quickRatio": 1.271, "currentRatio": 1.523, "totalRevenue": 147752000, "revenuePerShare": 1.518, "returnOnAssets": -0.35536, "freeCashflow": -220020624, "operatingCashflow": -315020992, "revenueGrowth": -0.21, "grossMargins": -1.09364, "ebitdaMargins": -1.92156, "operatingMargins": -3.81262, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]